Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Combination of alpha-2 receptor agonist (clonidin) and an anti-muscarinic agent (oxybutynin) for the treatment of sialorrhoea

A receptor agonist and agonist technology, which is used in combination of α2 receptor agonist (clonidine) and antimuscarinic drug (oxybutynin) for the treatment of salivation, can solve problems such as unsatisfactory

Inactive Publication Date: 2009-04-01
东方药业(萨摩亚)有限公司
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Alpha2 agonists are not ideal for the former; antimuscarinic drugs are not ideal for both

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combination of alpha-2 receptor agonist (clonidin) and an anti-muscarinic agent (oxybutynin) for the treatment of sialorrhoea
  • Combination of alpha-2 receptor agonist (clonidin) and an anti-muscarinic agent (oxybutynin) for the treatment of sialorrhoea

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0015] Preferred alpha2 adrenoceptor agonists for use in the present invention are clonidine, alaclonidine, brimonidine, rilmedinide, medetomidine, tizanidine, moxonidine and loxidine Fecidine. Preferred antimuscarinic drugs for use in the present invention are tolterodine, darfenacine, solifenacin, zafenacin, oxybutynin, tosbim, rivatropate, tiotropium Ammonium bromide and Ro-3202904 (PSD-506).

[0016] According to the invention, each active agent may be used in any suitable form, for example as a salt, hydrate or prodrug. In the case of chiral molecules, they may also be used in the form of racemates, non-racemic mixtures or essentially individual enantiomers.

[0017] In general, each active agent may be administered paralingually, sublingually or buccally in any suitable formulation. It is preferably formulated as a gum, spray, lozenge, lozenge or dispersible tablet.

[0018] The active agents can be formulated together in a single dosage form. Alternatively, they ma...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

An alpha2 adrenoreceptor agonist eg. clonidine, brimonidine, monoxidine, lofexidine is useful for the treatment of siaiorrhoea, administered by the paraungual, sublingual or buccal route. The patient to be treated is also given an anti-muscarinic agent eg. oxybutynin, glycopyrrolate, ipratropium.

Description

technical field [0001] The present invention relates to drug combinations and their use in the treatment of salivation. Background technique [0002] Patients with severe neurological impairments such as movement disorders (eg, cerebral palsy, peripheral neuromuscular disease, facial palsy, Parkinson's disease, severe mental retardation, and other conditions such as stroke and esophageal cancer) experience salivation (or drooling), which is The involuntary loss of saliva and other contents of the mouth. Salivation is common in individuals with neurological dysfunction. For example, socially significant salivation occurs in about 10% of patients with cerebral palsy. Persistent salivation beyond the age of 3 or 4 years is considered abnormal salivation. Salivation results from hypersalivation or from impaired swallowing, which is a particular problem in patients with motor impairment. [0003] Salivation causes speech disturbances, problems with eating and swallowing, and ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/415A61K31/216A61P43/00
Inventor 艾伦·杰弗里·罗奇保罗·戈德史密斯
Owner 东方药业(萨摩亚)有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com